<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313478303</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313478303</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Concise report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Posterior reversible encephalopathy syndrome in systemic lupus erythematosus: pooled analysis of the literature reviews and report of six new cases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Shaharir</surname><given-names>SS</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313478303">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203313478303"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Remli</surname><given-names>R</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313478303">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Marwan</surname><given-names>AA</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313478303">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Said</surname><given-names>MSM</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313478303">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kong</surname><given-names>NCT</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313478303">1</xref>
</contrib>
<aff id="aff1-0961203313478303"><label>1</label>Department of Internal Medicine, Universiti Kebangsaan Malaysia Medical Centre, Malaysia</aff>
<aff id="aff2-0961203313478303"><label>2</label>Department of Internal Medicine, Universiti Sains Islam Malaysia, Malaysia</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0961203313478303">Syahrul Sazliyana Shaharir, Department of Internal Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur. Email: <email>sazliyana@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>492</fpage>
<lpage>496</lpage>
<history>
<date date-type="received"><day>25</day><month>11</month><year>2012</year></date>
<date date-type="accepted"><day>17</day><month>1</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2013. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec9-0961203313478303"><title>Introduction</title>
<p>Posterior reversible encephalopathy syndrome (PRES) is a rare neurological disorder which is increasingly recognized to occur in systemic lupus erythematosus (SLE).</p>
</sec>
<sec id="sec10-0961203313478303"><title>Objective</title>
<p>The purpose of this study was to identify the characteristics of SLE patients with PRES and the associated factors of the poor outcome among them.</p>
</sec>
<sec id="sec11-0961203313478303"><title>Methods</title>
<p>We investigated SLE patients who developed PRES between 2005–2011 at the Universiti Kebangsaan Malaysia Medical Centre. A comprehensive literature search was done to find all published cases of PRES in SLE. Pooled analysis was conducted to identify the factors associated with poor outcome.</p>
</sec>
<sec id="sec12-0961203313478303"><title>Results</title>
<p>There were 103 cases of PRES in SLE published in the literature but only 87 cases were included in the analysis in view of incomplete individual data in the remaining cases. The majority of the cases were Asians (74.2%), female (95.4%) with mean age of 26.3 ± 8.8 years. PRES was highly associated with active disease (97.5%), hypertension (91.7%) and renal involvement (85.1%). We found that 79 patients had a full recovery (90.8%) with a mean onset of full clinical recovery in 5.6 ± 4.1 days. On univariate analysis and logistic regression analysis the predictors of poor outcome, defined as incomplete clinical recovery or death, were intracranial hemorrhage, odds ratio (OR) 14 (1.1–187.2), <italic>p </italic>= 0.04 and brainstem involvement in PRES, OR 10.9 (1.3–90.6), <italic>p </italic>= 0.003.</p>
</sec>
<sec id="sec13-0961203313478303"><title>Conclusion</title>
<p>Intracranial hemorrhage and brainstem involvement were the two important predictors of poor outcome of PRES. Larger prospective studies are needed to further delineate the risk of poor outcome among them.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Posterior reversible encephalopathy syndrome</kwd>
<kwd>renal</kwd>
<kwd>lupus</kwd>
<kwd>hemorrhage</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>edited-state</meta-name>
<meta-value>corrected-proof</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="sec1-0961203313478303" sec-type="intro"><title>Introduction</title>
<p>Posterior reversible encephalopathy syndrome (PRES) is a syndrome that results from the loss of cerebral autoregulation leading to extravasation of plasma proteins and cells into the extracellular space and cerebral edema. The exact pathophysiology of PRES is still not clear. Vasogenic edema mediated by high blood pressure is the most accepted theory that has been implicated in the pathogenesis of PRES.<sup><xref ref-type="bibr" rid="bibr1-0961203313478303">1</xref></sup> Endothelial dysfunction causing an increase in the capillary permeability and loss of autoregulation are also thought to play a pivotal role in the pathogenesis of PRES especially in autoimmune diseases, sepsis and eclampsia.<sup><xref ref-type="bibr" rid="bibr1-0961203313478303">1</xref></sup></p>
<p>The most common clinical presentations of PRES are headache, visual abnormalities and seizure. Up to 40% of these presentations are with severe manifestations such as reduced consciousness, coma and status epilepticus.<sup><xref ref-type="bibr" rid="bibr2-0961203313478303">2</xref></sup> Radiographic imaging commonly demonstrated focal regions of symmetrical hemispheric edema, especially at the occipital lobes. T2- and fluid attenuated inversion recovery (FLAIR)-weighted sequences typically demonstrate a symmetrical hyperintensity and edema involving subcortical and cortex areas of the above mentioned regions.<sup><xref ref-type="bibr" rid="bibr3-0961203313478303">3</xref></sup> We describe the diversity in the clinical and radiographic features of PRES complicating six patients with systemic lupus erythematosus (SLE) and subsequently conducted the first ever pooled analysis of the available cases from the literature to identify the characteristics and factors associated with poor outcome in PRES among SLE patients.</p>
</sec>
<sec id="sec2-0961203313478303" sec-type="methods"><title>Methods</title>
<p>We retrospectively reviewed the charts and magnetic resonance imaging (MRI) findings of six SLE patients from the Universiti Kebangsaan Malaysia Medical Centre who developed PRES from 2005–2011. An extensive review of the English language literature using PubMed database with keywords of ‘posterior reversible encephalopathy syndrome,’ ‘reversible posterior leukoencephalopathy syndrome,’ ‘systemic lupus erythematosus,’ and ‘lupus’ were performed. We also included pertinent articles obtained from searching references in the articles found in the primary search. Statistical analysis using the Statistical Package for the Social Sciences (SPSS) software version 18.0 was performed on the pooled data from the literature and six new cases from our institution, to identify the demographics and disease characteristics of lupus patients with PRES and those who had a poor outcome. Poor outcome was defined as incomplete clinical recovery or mortality. Results are expressed as mean ± standard deviation (SD) for normally distributed data, and as median (interquartile rang (IQR)) for non-normally distributed data. Intergroup comparison was performed by using the Mann Whitney U test for variables not normally distributed, the Student <italic>t</italic> test for normally distributed variables, and the χ<sup><xref ref-type="bibr" rid="bibr2-0961203313478303">2</xref></sup> test for dichotomous variables. Multiple imputation technique was performed since the missing data was more than 5% in random variables. Logistic regression analysis was performed on the imputed datasets to identify the predictors of poor outcome in PRES. Statistical significance was considered reached at <italic>p </italic>&lt; 0.05.</p>
</sec>
<sec id="sec3-0961203313478303" sec-type="results"><title>Results</title>
<sec id="sec4-0961203313478303" sec-type="cases"><title>Case reports</title>
<p>Six lupus patients were diagnosed as having posterior reversible encephalopathy syndrome (PRES) from 2005–2011 at the Universiti Kebangsaan Malaysia Medical Centre. All of them fulfilled the classification criteria for SLE. Their demographics and disease characteristics are summarized in <xref ref-type="table" rid="table1-0961203313478303">Table 1</xref>. All of them had active lupus nephritis and their initial presentations were seizure or status epilepticus. The diagnosis was made based on the typical focal edema changes which affect subcortical and cortex symmetrically on brain computed tomography (CT) or MRI. MRI studies also typically demonstrated an increased signal intensity on T2 and FLAIR- weighted sequences with no restriction diffusion on diffusion-weighted images (DWI) during acute setting. However, Case 2 had more extensive involvement of the cerebellar and midbrain region with focal subarachnoid hemorrhage at the left parietal region. Repeat MRI or CT scan for Case 1 and 2 showed improvement or resolution of the lesions after four days and three weeks respectively. Repeat MRI of Case 2 after 16 weeks showed residual lacunar infarct at the genu of left internal capsule, but the other lesions had resolved (<xref ref-type="fig" rid="fig1-0961203313478303">Figure 1(a) and (b)</xref>). There was no repeat imaging done for Cases 4,5 and 6 but all of them had full clinical recovery within 2–5 days (<xref ref-type="fig" rid="fig2-0961203313478303">Figure 2(a) and (b)</xref>).
<fig id="fig1-0961203313478303" position="float"><label>Figure 1</label><caption><p>Case 2. T2 weighted images showed hyperintense lesion (a) at the left centrum semiovale which subsequently resolved (b) in the repeated MRI 16 weeks later.</p></caption><graphic xlink:href="10.1177_0961203313478303-fig1.tif"/>
</fig>
<fig id="fig2-0961203313478303" position="float"><label>Figure 2</label><caption><p>MRI brain of Case 5. Multiple areas of high signal intensities on T2 in the bilateral cortex and subcortical region of (a) occipital lobes and (b) bilateral temporoparietal.</p></caption><graphic xlink:href="10.1177_0961203313478303-fig2.tif"/>
</fig>
<table-wrap id="table1-0961203313478303" position="float"><label>Table 1</label><caption><p>Clinical characteristics and neuroimaging results of systemic lupus erythematosus (SLE) patients with posterior reversible encephalopathy syndrome (PRES)</p></caption>
<graphic alternate-form-of="table1-0961203313478303" xlink:href="10.1177_0961203313478303-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Case</th>
<th>Age (years)/ gender/ race</th>
<th>Disease duration</th>
<th>Active disease<sup><xref ref-type="table-fn" rid="table-fn2-0961203313478303">a</xref></sup></th>
<th>Lupus</th>
<th>Recent treatment(≤3 months before PRES onset)</th>
<th>Blood pressure (mmHg)</th>
<th>SCr (µmol/L)</th>
<th>UPCI (g/mmol creat)</th>
<th>Clinical presentation</th>
<th>Brain imaging changes</th>
<th>Clinical recovery (days)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>1</td>
<td>17/f/I</td>
<td>3 years</td>
<td>Yes</td>
<td>LN III/V</td>
<td>Pred, CyA</td>
<td>233/120</td>
<td>719</td>
<td>0.27</td>
<td>H, SE(Intubated)</td>
<td>Bilat O</td>
<td>2</td>
</tr>
<tr>
<td rowspan="2">2</td>
<td rowspan="2">30/f/M</td>
<td rowspan="2">2 years</td>
<td rowspan="2">Yes</td>
<td>LN IV/V, 20% crescents,</td>
<td rowspan="2">Pred, CYC</td>
<td rowspan="2">230/134</td>
<td rowspan="2">79</td>
<td rowspan="2">0.52</td>
<td rowspan="2">H, SE(Intubated)</td>
<td>Bilat frontal, BG, thalamus, midbrain, cereb</td>
<td rowspan="2">7</td>
</tr>
<tr>
<td>APLS</td>
<td>SAH</td>
</tr>
<tr>
<td>3</td>
<td>25/f/M</td>
<td>6 years</td>
<td>Yes</td>
<td>LN IV/V, 20% crescents</td>
<td>Pred, CYC</td>
<td>140/100</td>
<td>150</td>
<td>0.2</td>
<td>H, GTC</td>
<td>Bilat O, P</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>22/f/C</td>
<td>7 years</td>
<td>Yes</td>
<td>LN IV/V, 20% crescents</td>
<td>Pred, CyA</td>
<td>140/50</td>
<td>114</td>
<td>0.45</td>
<td>H, GTC</td>
<td>Bilat O, F</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>23/f/I</td>
<td>3 months</td>
<td>Yes</td>
<td>LN III/V</td>
<td>Pred 1 mg/kg/day</td>
<td>210/120</td>
<td>138</td>
<td>0.14</td>
<td>H, SE(Intubated)</td>
<td>Bilat, O, T, P</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>46/f/C</td>
<td>5 years</td>
<td>Yes</td>
<td>LN IV</td>
<td>Pred, Cellcept</td>
<td>196/111</td>
<td>117</td>
<td>0.23</td>
<td>H, CB, Right hemiparesis, SE(Intubated)</td>
<td>Bilat O, T, P, F</td>
<td>5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313478303"><p>Bilat: bilateral; C: Chinese; Cereb: cerebellar; CB: cortical blindness; f: female; F: frontal; GTC: generalized tonic clonic; H: headache; I: Indian; LN: lupus nephritis; M: Malay; O: occipital; P: parietal; Pred: Prednisolon; SAH: subarachnoid hemorrhage SCr: serum creatinine; SE: status epilepticus; T: temporal; UPCI: urine protein creatinine index. CyA: Cyclosporine A; CYC: Cyclophosphamide.</p></fn>
<fn id="table-fn2-0961203313478303"><label>a</label><p>Active disease was defined as SLE Disease Activity Index (SLEDAI) score of ≥4.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec5-0961203313478303"><title>Literature review and pooled analysis of cases</title>
<p>We found 103 well-described cases in the English language literature of PRES syndrome occurring in SLE patients.<sup><xref ref-type="bibr" rid="bibr4-0961203313478303">4</xref>–<xref ref-type="bibr" rid="bibr13-0961203313478303">13</xref></sup> Baizabal-Carvallo et al. reported 22 PRES cases which occurred in their single cohort of 21 SLE patients in Mexico.<sup><xref ref-type="bibr" rid="bibr14-0961203313478303">14</xref></sup> Meanwhile, Muscal et al. reported another six cases of PRES in their single cohort of adolescents with lupus.<sup><xref ref-type="bibr" rid="bibr15-0961203313478303">15</xref></sup> We describe six more PRES cases in SLE in this paper. Including our six new reported cases, a total of 87 cases were analyzed. Both studies by Baizabal-Carvallo et al. and Muscal et al. were excluded since there were no individual data for their cohorts. <xref ref-type="table" rid="table2-0961203313478303">Table 2</xref> demonstrates the characteristics of SLE patients with PRES.
<table-wrap id="table2-0961203313478303" position="float"><label>Table 2</label><caption><p>Demographics and disease characteristics of the 87 lupus patients with posterior reversible encephalopathy syndrome (PRES)</p></caption>
<graphic alternate-form-of="table2-0961203313478303" xlink:href="10.1177_0961203313478303-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Demographics and disease characteristics</th>
<th>Percentage</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Female gender (<italic>n </italic>= 87)</td>
<td>95.4%</td>
</tr>
<tr>
<td colspan="2">Race (<italic>n </italic>= 61)</td>
</tr>
<tr>
<td> Asian</td>
<td>74.2%</td>
</tr>
<tr>
<td> Hispanic</td>
<td>16.4%</td>
</tr>
<tr>
<td> Caucasian</td>
<td>6.6%</td>
</tr>
<tr>
<td> Others</td>
<td>2.8%</td>
</tr>
<tr>
<td>Age (years)</td>
<td>26.3 ± 8.8 years</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>4.4 ± 1.3 years</td>
</tr>
<tr>
<td>Hypertension (<italic>n </italic>= 85)</td>
<td>91.7%</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>179.3 ± 32</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>106.9 ± 4.1</td>
</tr>
<tr>
<td>Active disease (<italic>n </italic>= 79)</td>
<td>97.5%</td>
</tr>
<tr>
<td>Renal involvement (<italic>n </italic>= 84)</td>
<td>85.1%</td>
</tr>
<tr>
<td>APLS (<italic>n </italic>= 87)</td>
<td>10.5%</td>
</tr>
<tr>
<td>Serum creatinine (mmol/L)</td>
<td>235.6 ± 173.2</td>
</tr>
<tr>
<td>Recent exposure to immunosuppressants (≤3 months before onset of PRES), <italic>n </italic>= 77</td>
<td>64.9%, <italic>n </italic>= 50</td>
</tr>
<tr>
<td> High dose prednisolon≥1 mg/kg</td>
<td>50%, <italic>n </italic>= 25</td>
</tr>
<tr>
<td> Cyclophosphamide</td>
<td>22%, <italic>n </italic>= 11</td>
</tr>
<tr>
<td> Cyclosporine A</td>
<td>12%, <italic>n </italic>= 6</td>
</tr>
<tr>
<td> Mycophenolate</td>
<td>8%, <italic>n </italic>= 4</td>
</tr>
<tr>
<td> Azathioprine</td>
<td>8%, <italic>n </italic>= 4</td>
</tr>
<tr>
<td> Rituximab</td>
<td>2%, <italic>n </italic>= 1</td>
</tr>
<tr>
<td colspan="2">Clinical presentation (<italic>n </italic>= 87)</td>
</tr>
<tr>
<td> Seizure</td>
<td>78.2%</td>
</tr>
<tr>
<td> Headache</td>
<td>60.9%</td>
</tr>
<tr>
<td> Altered conscious level</td>
<td>54.5%</td>
</tr>
<tr>
<td> Visual abnormalities</td>
<td>47.1%</td>
</tr>
<tr>
<td colspan="2">Radiographic changes (<italic>n </italic>= 70)</td>
</tr>
<tr>
<td> Bilateral/symmetrical</td>
<td>95.7%</td>
</tr>
<tr>
<td> Unilateral</td>
<td>5.7%</td>
</tr>
<tr>
<td> Brainstem</td>
<td>11.4%</td>
</tr>
<tr>
<td> Cerebellum</td>
<td>22.9%</td>
</tr>
<tr>
<td> Hemorrhagic</td>
<td>8.7%</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203313478303"><p>APLS: antiphospholipid syndrome.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>We found that 79 patients made a full recovery (90.8%) with a mean onset of full clinical recovery in 5.6 ± 4.1 days. No correlation was found between age, systolic and diastolic blood pressure, serum creatinine, recent immunosuppressants exposure (≤3 months before onset of PRES), cyclosporine use and antiphospholipid syndrome with poor outcome of PRES in SLE. A significantly higher percentage of patients with brainstem involvement (<italic>n </italic>= 8) had no full recovery, which was 37.5% compared to 4.8% among those who did not have brainstem involvement, <italic>p </italic>= &lt; 0.002. Apart from that, among those who had intracranial hemorrhage (<italic>n </italic>= 6), a significantly higher percentage did not recover fully, 33.3% compared to 6.3% among those who did not have hemorrhagic changes on presentation of PRES. On further analysis by logistic regression analysis of the imputed datasets, these factors remained as significant predictors of failure of full clinical recovery, even after adjustment for the age, systolic and diastolic blood pressure and serum creatinine. <xref ref-type="table" rid="table3-0961203313478303">Table 3</xref> shows the regression analysis of factors associated with full recovery of PRES among the lupus cohort.
<table-wrap id="table3-0961203313478303" position="float"><label>Table 3</label><caption><p>Logistic regression of independent predictors for poor outcome of posterior reversible encephalopathy syndrome (PRES) in systemic lupus erythematosus (SLE) cohort</p></caption>
<graphic alternate-form-of="table3-0961203313478303" xlink:href="10.1177_0961203313478303-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Parameters</th>
<th>B coefficient</th>
<th>Odds ratio (95% CI)</th>
<th><italic>p</italic> value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Brainstem involvement</td>
<td>2.39</td>
<td>10.9 (1.3–90.6)</td>
<td>0.003</td>
</tr>
<tr>
<td>Intracranial hemorrhage</td>
<td>2.7</td>
<td>14.0 (1.1–187.2)</td>
<td>0.04</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>0.01</td>
<td>1.01 (0.97–1.04)</td>
<td>0.6</td>
</tr>
<tr>
<td>Diastolic blood pressure</td>
<td>0.01</td>
<td>1.0 (0.9–1.1)</td>
<td>0.9</td>
</tr>
<tr>
<td>Age</td>
<td>0.02</td>
<td>1.0 (0.8–1.1)</td>
<td>0.7</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.04</td>
<td>1.0 (0.9–1.0)</td>
<td>0.6</td>
</tr>
<tr>
<td>Cyclosporine use</td>
<td>0.60</td>
<td>1.83 (0.19–17.9)</td>
<td>0.6</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0961203313478303"><p>CI: confidence interval.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
</sec>
<sec id="sec6-0961203313478303" sec-type="discussion"><title>Discussion</title>
<p>From the pooled analysis, the majority of the cases occurred among those with active disease, renal involvement and among Asian lupus patients. Whether PRES is one of the spectrum manifestations of neuropsychiatric SLE (NPSLE) remains controversial. Although the majority of PRES cases are reversible clinically and radiologically, a few patients are left with residual damage especially if the PRES is not promptly recognized and the seizure and hypertension are not properly managed. Vasogenic edema can progress to cytotoxic edema and subsequently transform into infarcts.<sup><xref ref-type="bibr" rid="bibr16-0961203313478303">16</xref></sup> Using univariate and multivariate analysis in this study, brainstem involvement and intracranial hemorrhage were the important predictors of poor outcome among lupus patients with PRES.</p>
<p>Brainstem involvement in PRES is rare and has been described in few case reports.<sup><xref ref-type="bibr" rid="bibr17-0961203313478303">17</xref></sup> Posterior edema, particularly when located in the cerebellum and brainstem, may cause transtentorial cerebral herniation<sup><xref ref-type="bibr" rid="bibr18-0961203313478303">18</xref></sup> and subsequently may lead to poor outcome.</p>
<p>Cerebral hemorrhage is also uncommon in PRES, reported to be around 5–17%.<sup><xref ref-type="bibr" rid="bibr2-0961203313478303">2</xref>,<xref ref-type="bibr" rid="bibr17-0961203313478303">17</xref></sup> Hemorrhage may occur due to small vessel rupture<sup><xref ref-type="bibr" rid="bibr1-0961203313478303">1</xref></sup> and previous reports showed that it may be more common among patients with allogeneic bone marrow transplantation or anticoagulant treatment, whereas blood pressure levels may have no influence on the bleeding risk.<sup><xref ref-type="bibr" rid="bibr19-0961203313478303">19</xref></sup> Consistent with one previous study,<sup><xref ref-type="bibr" rid="bibr20-0961203313478303">20</xref></sup> our pooled analysis also showed that intracranial hemorrhage in PRES is associated with an increased morbidity and mortality.</p>
<p>Hypertension is the most well recognized risk factor for PRES as high blood pressure disrupts the cerebrovascular autoregulation leading to vasogenic edema.<sup><xref ref-type="bibr" rid="bibr21-0961203313478303">21</xref></sup> However, the severity of hypertension is not significantly associated with the intensity of the clinical and radiological manifestation of PRES.<sup><xref ref-type="bibr" rid="bibr3-0961203313478303">3</xref></sup> Several reported cases have also highlighted the role of other immunosuppressive agents which include cyclosporine A, tacrolimus, cyclophosphamide, steroids, intravenous immunoglobulins and rituximab as etiologies in PRES.<sup><xref ref-type="bibr" rid="bibr5-0961203313478303">5</xref></sup> However, one needs to consider that a high level of systemic activity of SLE,<sup><xref ref-type="bibr" rid="bibr14-0961203313478303">14</xref></sup> nephrotic state and renal failure are also recognized associations of PRES.<sup><xref ref-type="bibr" rid="bibr22-0961203313478303">22</xref></sup> Therefore the specific role of each drug is not clear since most of these drugs were given for active lupus nephritis.</p>
<p>In conclusion, our pooled analysis showed that both brainstem involvement and intracranial hemorrhage were the independent predictors of poor outcome in PRES. The limitation of our study was that a few records were missing data and therefore a larger prospective study or use of regional/international registries are needed to further delineate the risk and predictors of outcome of PRES cases in SLE.</p>
</sec>
</body>
<back>
<sec id="sec7-0961203313478303"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec8-0961203313478303"><title>Conflicts of interest</title>
<p>None declared.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313478303"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartynski</surname><given-names>WS</given-names></name></person-group>. <article-title>Posterior reversible encephalopathy syndrome, part 2: Controversies surrounding pathophysiology of vasogenic edema</article-title>. <source>AJNR Am J Neuroradiol</source> <year>2008</year>; <volume>29</volume>: <fpage>1043</fpage>–<lpage>1049</lpage>.</citation></ref>
<ref id="bibr2-0961203313478303"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>VH</given-names></name><name><surname>Wijdicks</surname><given-names>EF</given-names></name><name><surname>Manno</surname><given-names>EM</given-names></name><name><surname>Rabinstein</surname><given-names>AA</given-names></name></person-group>. <article-title>Clinical spectrum of reversible posterior leukoencephalopathy syndrome</article-title>. <source>Arch Neurol</source> <year>2008</year>; <volume>65</volume>: <fpage>205</fpage>–<lpage>210</lpage>.</citation></ref>
<ref id="bibr3-0961203313478303"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartynski</surname><given-names>WS</given-names></name><name><surname>Boardman</surname><given-names>JF</given-names></name></person-group>. <article-title>Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome</article-title>. <source>AJNR Am J Neuroradiol</source> <year>2007</year>; <volume>28</volume>: <fpage>1320</fpage>–<lpage>1327</lpage>.</citation></ref>
<ref id="bibr4-0961203313478303"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>CE</given-names></name><name><surname>Leclerc</surname><given-names>R</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Fortin</surname><given-names>PR</given-names></name></person-group>. <article-title>Posterior reversible encephalopathy syndrome: An emerging disease manifestation in systemic lupus erythematosus</article-title>. <source>Semin Arthritis Rheum</source> <year>2011</year>; <volume>41</volume>: <fpage>353</fpage>–<lpage>363</lpage>.</citation></ref>
<ref id="bibr5-0961203313478303"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leroux</surname><given-names>G</given-names></name><name><surname>Sellam</surname><given-names>J</given-names></name><name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Posterior reversible encephalopathy syndrome during systemic lupus erythematosus: Four new cases and review of the literature</article-title>. <source>Lupus</source> <year>2008</year>; <volume>17</volume>: <fpage>139</fpage>–<lpage>147</lpage>.</citation></ref>
<ref id="bibr6-0961203313478303"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YX</given-names></name><name><surname>Liu</surname><given-names>JR</given-names></name><name><surname>Ding</surname><given-names>MP</given-names></name><etal/></person-group>. <article-title>Reversible posterior encephalopathy syndrome in systemic lupus erythematosus and lupus nephritis</article-title>. <source>Intern Med</source> <year>2008</year>; <volume>47</volume>: <fpage>867</fpage>–<lpage>875</lpage>.</citation></ref>
<ref id="bibr7-0961203313478303"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El Karoui</surname><given-names>K</given-names></name><name><surname>Le Quintrec</surname><given-names>M</given-names></name><name><surname>Dekeyser</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Posterior reversible encephalopathy syndrome in systemic lupus erythematosus</article-title>. <source>Nephrol Dial Transplant</source> <year>2008</year>; <volume>23</volume>: <fpage>757</fpage>–<lpage>763</lpage>.</citation></ref>
<ref id="bibr8-0961203313478303"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varaprasad</surname><given-names>IR</given-names></name><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Prabu</surname><given-names>VN</given-names></name><name><surname>Rajasekhar</surname><given-names>L</given-names></name><name><surname>Kanikannan</surname><given-names>MA</given-names></name><name><surname>Narsimulu</surname><given-names>G</given-names></name></person-group>. <article-title>Posterior reversible encephalopathy syndrome in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2011</year>; <volume>38</volume>: <fpage>1607</fpage>–<lpage>1611</lpage>.</citation></ref>
<ref id="bibr9-0961203313478303"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kadikoy</surname><given-names>H</given-names></name><name><surname>Haque</surname><given-names>W</given-names></name><name><surname>Hoang</surname><given-names>V</given-names></name><name><surname>Maliakkal</surname><given-names>J</given-names></name><name><surname>Nisbet</surname><given-names>J</given-names></name><name><surname>Abdellatif</surname><given-names>A</given-names></name></person-group>. <article-title>Posterior reversible encephalopathy syndrome in a patient with lupus nephritis</article-title>. <source>Saudi J Kidney Dis Transpl</source> <year>2012</year>; <volume>23</volume>: <fpage>572</fpage>–<lpage>576</lpage>.</citation></ref>
<ref id="bibr10-0961203313478303"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dilek</surname><given-names>NO</given-names></name><name><surname>Gulay</surname><given-names>K</given-names></name><name><surname>Emel</surname><given-names>U</given-names></name><name><surname>Forta</surname><given-names>H</given-names></name></person-group>. <article-title>Posterior reversible encephalopathy syndrome in systemic lupus erythematosus</article-title>. <source>Neurol India</source> <year>2009</year>; <volume>5</volume>: <fpage>497</fpage>–<lpage>499</lpage>.</citation></ref>
<ref id="bibr11-0961203313478303"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Hurley</surname><given-names>RM</given-names></name></person-group>. <article-title>Posterior reversible encephalopathy syndrome in SLE nephritis</article-title>. <source>Postgrad Med J</source> <year>2008</year>; <volume>84</volume>: <fpage>56</fpage>–<lpage>56</lpage>.</citation></ref>
<ref id="bibr12-0961203313478303"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monteiro</surname><given-names>C</given-names></name><name><surname>Almeida</surname><given-names>I</given-names></name><name><surname>Dias</surname><given-names>D</given-names></name><name><surname>Santos</surname><given-names>E</given-names></name></person-group>. <article-title>Atypical posterior reversible encephalopathy syndrome: a flare of systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2012</year>; <volume>39</volume>: <fpage>195</fpage>–<lpage>196</lpage>.</citation></ref>
<ref id="bibr13-0961203313478303"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sulaiman</surname><given-names>WHN</given-names></name><name><surname>Baba</surname><given-names>MS</given-names></name></person-group>. <article-title>Posterior reversible encephalopathy in undiagnosed systemic lupus erythematosus: a case report</article-title>. <source>Oman Med J</source> <year>2011</year>; <volume>26–28</volume>.</citation></ref>
<ref id="bibr14-0961203313478303"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baizabal-Carvallo</surname><given-names>JF</given-names></name><name><surname>Barragan-Campos</surname><given-names>HM</given-names></name><name><surname>Padilla-Aranda</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Posterior reversible encephalopathy syndrome as a complication of acute lupus activity</article-title>. <source>Clin Neurol Neurosurg</source> <year>2009</year>; <volume>111</volume>: <fpage>359</fpage>–<lpage>363</lpage>.</citation></ref>
<ref id="bibr15-0961203313478303"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muscal</surname><given-names>E</given-names></name><name><surname>Traipe</surname><given-names>E</given-names></name><name><surname>de Guzman</surname><given-names>MM</given-names></name><name><surname>Myones</surname><given-names>BL</given-names></name><name><surname>Brey</surname><given-names>RL</given-names></name><name><surname>Hunter</surname><given-names>JV</given-names></name></person-group>. <article-title>MR imaging findings suggestive of posterior reversible encephalopathy syndrome in adolescents with systemic lupus erythematosus</article-title>. <source>Pediatr Radiol</source> <year>2010</year>; <volume>40</volume>: <fpage>1241</fpage>–<lpage>1245</lpage>.</citation></ref>
<ref id="bibr16-0961203313478303"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stott</surname><given-names>VL</given-names></name><name><surname>Hurrell</surname><given-names>MA</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name></person-group>. <article-title>Reversible posterior leukoencephalopathy syndrome: A misnomer reviewed</article-title>. <source>Intern Med J</source> <year>2005</year>; <volume>35</volume>: <fpage>83</fpage>–<lpage>90</lpage>.</citation></ref>
<ref id="bibr17-0961203313478303"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKinney</surname><given-names>AM</given-names></name><name><surname>Short</surname><given-names>J</given-names></name><name><surname>Truwit</surname><given-names>CL</given-names></name><etal/></person-group>. <article-title>Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings</article-title>. <source>AJR Am J Roentgenol</source> <year>2007</year>; <volume>189</volume>: <fpage>904</fpage>–<lpage>912</lpage>.</citation></ref>
<ref id="bibr18-0961203313478303"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belogolovkin</surname><given-names>V</given-names></name><name><surname>Levine</surname><given-names>SR</given-names></name><name><surname>Fields</surname><given-names>MC</given-names></name><name><surname>Stone</surname><given-names>JL</given-names></name></person-group>. <article-title>Postpartum eclampsia complicated by reversible cerebral herniation</article-title>. <source>Obstet Gynecol</source> <year>2006</year>; <volume>107</volume>: <fpage>442</fpage>–<lpage>445</lpage>.</citation></ref>
<ref id="bibr19-0961203313478303"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hefzy</surname><given-names>HM</given-names></name><name><surname>Bartynski</surname><given-names>WS</given-names></name><name><surname>Boardman</surname><given-names>JF</given-names></name><name><surname>Lacomis</surname><given-names>D</given-names></name></person-group>. <article-title>Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features</article-title>. <source>AJNR Am J Neuroradiol</source> <year>2009</year>; <volume>30</volume>: <fpage>1371</fpage>–<lpage>1379</lpage>.</citation></ref>
<ref id="bibr20-0961203313478303"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aranas</surname><given-names>RM</given-names></name><name><surname>Prabhakaran</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>VH</given-names></name></person-group>. <article-title>Posterior reversible encephalopathy syndrome associated with hemorrhage</article-title>. <source>Neurocrit Care</source> <year>2009</year>; <volume>10</volume>: <fpage>306</fpage>–<lpage>312</lpage>.</citation></ref>
<ref id="bibr21-0961203313478303"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hinchey</surname><given-names>J</given-names></name><name><surname>Chaves</surname><given-names>C</given-names></name><name><surname>Appignani</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>A reversible posterior leukoencephalopathy syndrome</article-title>. <source>N Engl J Med</source> <year>1996</year>; <volume>334</volume>: <fpage>494</fpage>–<lpage>500</lpage>.</citation></ref>
<ref id="bibr22-0961203313478303"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishikura</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Hamasaki</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome</article-title>. <source>Nephrol Dial Transplant</source> <year>2008</year>; <volume>23</volume>: <fpage>2531</fpage>–<lpage>2536</lpage>.</citation></ref>
</ref-list>
</back>
</article>